NIH Influence Allegations: A whistleblower claims Bill Gates used large donations to the NIH via the Foundation for the National Institutes of Health to steer research priorities toward the Gates Foundation, raising questions about safeguards meant to block private influence. Obesity Drug Safety Debate: New reporting highlights concerns that rapid weight loss on GLP-1s may include substantial lean muscle loss, prompting calls to better protect muscle during treatment. UK Weight-Loss Pills Go Oral: Britain’s regulator approved Novo Nordisk’s oral Wegovy (semaglutide), giving patients a needle-free option and intensifying competition with Eli Lilly’s oral GLP-1 efforts. Biotech Market Volatility: Summit Therapeutics pulled a planned $500M secondary share offering after mixed Phase 3 results for ivonescimab, showing how clinical uncertainty can hit fundraising plans fast. Rare Disease & Pharma Deals: Chiesi completed its $1.9B acquisition of KalVista, adding EKTERLY for hereditary angioedema to its rare-disease portfolio. Cybersecurity & Staffing Pressure: A new piece warns ransomware targeting smaller health providers is rising, while a University of Michigan study finds COVID-era nurse job shifts were driven by burnout and staffing shortfalls. Public Health Reminder: World Pertussis Day coverage stresses whooping cough isn’t just a childhood disease and supports life-course vaccination, including during pregnancy.